Partnerships

Validating the platform with strategic partners

Rani's partnerships bring together best-in-class biologics with the RaniPill® delivery platform — combining partner development funding and commercial infrastructure with Rani's manufacturing, preclinical, clinical, and regulatory expertise.

Featured Partnership

A billion-dollar collaboration with Chugai Pharmaceutical

Rani recently completed a billion-dollar collaboration with Chugai Pharmaceutical, a top pharmaceutical company. This is one of two major pharmaceutical partnerships that validate the RaniPill® platform and its reliability.

The collaboration starts in hemophilia — a rare disease where precise dosing is crucial and under-treatment can have serious impact. Focusing on rare disease reflects confidence in the platform's ability to provide consistent, injection-level performance in high-stakes situations.

Partner with us →
$1B+
Total potential collaboration value with Chugai Pharmaceutical
11
Predefined targets in the negotiated agreement
5
Targets sharing the same financial terms as the original deal
50/50
Co-development partnership with ProGen for RT-114
Partnership Model

A complementary collaboration model

Partners contribute development funding and commercial infrastructure. Rani provides the enabling delivery platform and end-to-end execution capabilities — reducing capital requirements and letting each side focus on its core strengths.

Technology License
Partners provide upfront, milestone, and program-level funding that supports advancement across the RaniPill® portfolio.
Commercial Infrastructure
Established global commercial reach, distribution, and patient access that bring approved oral biologics to scale.
Enabling Delivery Platform
Rani contributes the RaniPill® robotic capsule — the platform that turns injectable biologics into oral therapies.
Manufacturing Capabilities
Vertically integrated manufacturing supports rapid product iteration and scale-up across partner programs.
Preclinical, Clinical & Regulatory
End-to-end development support — preclinical studies, clinical execution, and regulatory strategy across geographies.
Capital-Efficient Focus
Reduces the capital requirements of traditional models and lets Rani concentrate on its core platform expertise.

Interested in partnering with Rani?

The RaniPill® platform is capable of delivering any payload orally, including proteins, peptides, and antibodies.

Partner with us → View Pipeline